



Organisation  
of European  
Cancer Institutes



# Oncology Days

 **ECI 47**

**WORKING TOGETHER TO IMPROVE  
QUALITY AND REDUCE INEQUALITIES**

# ATHENS 2025

**GENERAL ASSEMBLY AND  
SCIENTIFIC PROGRAMME**

*11 - 13 June 2025*

*Royal Olympic Hotel*



**FINAL  
PROGRAMME**

## President's Welcome

Cancer is the second leading cause of death in Europe, already the first for people over 65, and the combination of three factors - failure to control major risk factors, longer life expectancy and our increased ability to treat and cure - will lead to an increase in incidence and prevalence.

In Europe, the determinants of quality of care vary widely both between and within countries, leading to considerable variation in outcomes. The European Union Cancer Plans, through a series of Joint Actions and competitive calls for proposals, aim to increase knowledge, reduce inequalities and ensure uniform quality of care by minimising barriers to access to diagnostic and therapeutic innovations.

The fragmentation of high quality cancer care needs to be reduced and clinical cancer care should be concentrated in hospital settings with proven clinical expertise and structured organisation. At the European level, this is reflected in the growing commitment to the establishment of accredited cancer centres and national cancer infrastructures in EU countries, with the aim of encouraging associated countries to join this initiative. Cancer care provides a powerful example of the need for patient-centred organisation, advanced care flow methods and seamless transitions between care settings. In this context, a strong European organisation of cancer institutes, such as the OECl, plays a crucial role in promoting quality in cancer care and research. This is why we have made a concerted effort to revitalise the OECl Patients Working Group, launching a programme to connect patient organisations with OECl members and involving the group in various EC projects.

It may not be enough to improve the quality of the European Institutes, increase our competences and involve the relevant stakeholders. First and foremost, we need to step up our efforts to communicate the benefits of belonging to this community.

This was one of the main objectives of the OECl Presidential Programme 2023-2026, first presented in Paris and reaffirmed at the 2024 Oncology Days in Helsinki. Many of the initiatives of the Presidential Programme were either launched or planned for 2024, and 2025 is the central year of my Presidency in which all the objectives should be realised.

As we reach the midpoint of my presidency, I have focused on better understanding the OECl's mandate and exploring ways in which our organisation can respond more effectively to the needs of society, patients and our members. This reflection has resulted in the OECl President's Strategy, which will be fully implemented by June 2026.

What does OECl offer its institutes and their members?

Firstly, the opportunity to join the A&D programme; secondly, to participate in the work of our four Working Groups; thirdly, to collaborate in current and future European projects; and finally, to attend our annual meetings, most recently in Athens. During 2024, we also launched two other initiatives: the OECl Academy, a mix-mode learning course aimed at training our clinicians and researchers on how to participate in European calls for proposals; and we set up a Young People's Board to advise the President and the Board of Directors on the role and scope of OECl, reflecting our commitment to investing in the younger generations who represent the future of European oncology. Other initiatives are under discussion within our Board of Directors, such as the provision of support programmes for our institutions, such as coaching, twinning and funding arrangements.

Another emerging challenge requires us to rethink approaches to early diagnosis, treatment, and long-term care: the integration of Artificial Intelligence (AI) in the healthcare sector promises better medicine. AI is used in medical diagnostics to analyse radiological images and identify pathologies with greater precision than traditional methods, improving in many cases the timeliness of diagnosis and the effectiveness of treatments.

AI has the potential to drive health innovation, enhancing prevention, diagnosis, treatment, and patient management, while improving recovery rates, fostering health innovation integration, and benefiting patients and society alike. In 2023 in Paris, we opened a dialogue on AI, and we will continue this conversation in Athens focusing on the use of AI to advance healthcare. By embracing AI, we aim not only to refine patient care but also improving operational efficiencies. Consistent with EU's vision for AI, we aspire to foster a multidisciplinary approach that integrates clinical and technological expertise, promotes preventive strategies, and raises health outcomes across Europe and beyond.

To conclude, my overarching objective for the OECl during my presidency is to strengthen and redefine our organisation's identity through its unique array of activities on the European stage. Our goal remains to represent Europe's cancer centres with inclusivity at our core. We will fulfil the expectations of society and patients only when all major cancer stakeholders move in the same direction, defining a shared agenda to enhance cancer control and deliver the best available treatments to every patient.

I want to extend my gratitude to everyone who has voluntarily contributed to our initiatives, all of which will be showcased here in Athens in an agenda that addresses some of the most pressing challenges facing the cancer community today.

For the third time, European Cancer Centre Directors are gathering in Greece, a country that, since the OECl's inception, has shown exceptional commitment to our Organisation.

A special thank you goes to the General Oncology Hospital of Athens "Saint Savvas", to all personnel involved in organizing OECl47, and Olga Balaoura, CEO of the 1<sup>st</sup> Health Region of Greece, a valued Board Member and a tremendous asset to the entire OECl community.



Giovanni Apolone  
OECl President

*Giovanni Apolone*



# Oncology Days

17-19 June 2026 Warsaw, Poland

GENERAL ASSEMBLY  
SCIENTIFIC CONFERENCES  
AND RELATED EVENTS

In collaboration with  
Maria Skłodowska-Curie  
**National Research  
Institute of Oncology**



Organisation  
of European  
Cancer Institutes  
European Economic  
Interest Grouping



DEVELOPING  
THE FUTURE IN  
COMPREHENSIVE  
CANCER CARE

## OECI2025 ONCOLOGY DAYS

### Dear Esteemed Participants


It is with great pleasure and deep honor that we welcome you to the OECI Oncology Days 2025, hosted by the General Oncology Hospital of Athens 'Saint Savvas' in the beautiful city of Athens, Greece. As a leading institution dedicated to cancer care, research, and innovation, it is both a privilege and a responsibility for us to host this prestigious gathering of distinguished experts, clinicians, researchers, and healthcare professionals from across Europe and beyond. This event offers a unique opportunity for collaboration, the exchange of knowledge, and the advancement of cancer care practices that place patients at the heart of our mission.

Greece, with its rich history of scientific inquiry and philosophical thought, serves as an inspiring backdrop for our collective efforts to push the boundaries of oncology care. At Saint Savvas, we are proud to contribute to this legacy through our ongoing research initiatives, cutting-edge clinical practices, and strong international collaborations.

This year's scientific programme has been thoughtfully curated to address some of the most pressing and innovative topics in oncology today. The sessions will delve into the transformative potential of Artificial Intelligence in cancer prevention, diagnosis, and treatment, offering insights into how AI can enhance multidisciplinary team decisions and radiotherapy planning. Another key focus will be on the evolution of oncology care at home, exploring how technology and innovative treatment models can bring quality cancer care directly to patients' homes, ensuring continuity and compassion in every step of their journey.


Beyond the conference, we invite you to immerse yourself in the vibrant culture and timeless beauty of Athens. From the iconic Acropolis and the historic Plaka district to the bustling markets of Monastiraki and the breathtaking views from Lycabettus Hill, the city offers a rich tapestry of experiences. Discover ancient history, savor traditional Greek cuisine, and enjoy the warmth and hospitality for which Greece is renowned.

We extend our heartfelt thanks to the Organisation of European Cancer Institutes (OECI) for entrusting us with this important role. We also express our deepest gratitude to all participants for their commitment to advancing oncology care. Your presence here is a testament to the spirit of collaboration and shared dedication that drives the global cancer care community forward. On behalf of the entire team at Saint Savvas General Oncology Hospital and the 1st Regional Health Authority, I wish you a productive, engaging, and memorable conference experience, as well as an unforgettable stay in Athens.



**Olga Balaoura**  
CEO of the 1st Health Region of Greece

## The OECI Network



The OECI is a non-governmental Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping.



OECI presently comprises 157 Members,

which include some of the most prominent European Comprehensive Cancer Centres.

Several major cancer centres from the Chile, Colombia, Jordan, Lebanon, Russian Federation, Tanzania, Turkey, Ukraine and Viet Nam are also members of the Organisation in order to benefit from the Accreditation and Designation Programme and to be involved in the activities promoted by the Working Groups.

The OECI aim is to accelerate the application of multidisciplinary personalised care approaches to reduce mortality and to guarantee an equitable access to care to all cancer patients.

- OECI Member A&D certified Comprehensive Cancer Network
- ★ OECI Member A&D certified Comprehensive Cancer Centre
- ★ OECI Member A&D certified Cancer Centre
- ★ OECI Member in the A&D process
- OECI Member





## The OECI membership

### Algeria

- ★ Anti-Cancer Center Blida Algeria Specialized Hospital Control Against Cancer, Bilda

### Austria

- ★ Comprehensive Cancer Center Vienna, Vienna

### Belgium

- ★ Institut Jules Bordet (JJB), Brussels
- ★ Leuven Kankerinstituut (LKI), Leuven
- ★ Kortrijk Kankercentrum az groeninge, Kortrijk
- ★ Oncologisch Centrum UZBrussel, Brussels
- ★ UZ Gent Kankercentrum, Ghent
- ★ Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

### Brazil

- ★ A.C. Camargo Cancer Centre, Sao Paulo

### Bulgaria

- ★ Multiprofile Hospital for Active Treatment Heart and Brain Pleven, Pleven
- ★ Bulgarian Joint Cancer Network (BJCN), Varna

### Chile

- ★ Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

### Colombia

- ★ Instituto Nacional de Cancerología ESE, Bogota

### Croatia

- ★ Klinika za tumore Klinički bolnički centar Sestre milosrdnice, Zagreb

### Cyprus

- ★ German Oncology Center (GOC), Limassol
- ★ Bank of Cyprus Oncology Centre, Nicosia

### Czech Republic

- ★ Masarykův onkologický ústav, Brno
- ★ Fakultní nemocnice v Motole, Prague
- ★ Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

### Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- ★ Aarhus Universitetshospital, Aarhus
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Department of oncology Rigshospitalet, Copenhagen
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Department for cancer treatment, Herlev and Gentofte Hospital, Herlev
- ★ Odense Universitetshospital, Odense

### Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- ★ North Estonia Medical Centre, Tallinn
- ★ AS Ida-Tallinna Keskhaigla, Tallinn

### Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku
- ★ TAYS Syöpäkeskus Tampereen Yliopistollinen Sairaala, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu
- ★ Kansallinen syöpäkeskus FICAN, Helsinki

### France

- ★ Association Toulousaine d'Oncologie Publique (ATOP), Toulouse
- ★ Centre Léon Bérard, Lyon
- ★ Gustave Roussy, Villejuif
- ★ Institut Curie, Paris

- ★ Institut Paoli – Calmettes, Marseille

- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse

- ★ Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université, Paris

- ★ Cancer Institute AP-HP. Nord - Université Paris Cité, Paris

- ★ Institut du cancer Paris CARPEM AP-HP.Centre-Université Paris Cité, Paris

- ★ Centre François Baclesse, Caen
- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain

- ★ Centre de lutte contre le cancer Eugène Marquis, Rennes

- ★ Centre Henri Becquerel, Rouen

- ★ ICANS Institut de cancérologie Strasbourg Europe, Strasbourg

- ★ Centre Jean Perrin, Clermont-Ferrand

- ★ Institut du Cancer de Montpellier (ICM), Montpellier

- ★ Centre Oscar Lambret, Lille

- ★ Institut Bergonié, Bordeaux

- ★ Centre Antoine Lacassagne, Nice

- ★ Institut Godinot, Reims

- ★ Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon

- ★ Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy

- ★ Institut Sainte Catherine, Avignon

### Germany

- ★ Deutsches Krebsforschungszentrum (DKFZ), Heidelberg

- ★ Nationales Centrum für Tumorerkrankungen Dresden NCT/UCC, Dresden

- ★ Charité Comprehensive Cancer Center, Berlin

- ★ Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt

- ★ Comprehensive Cancer Center München, Munich

- ★ Bayerisches Zentrum für Krebsforschung (BZKF), Erlangen

### Greece

- ★ General Oncology Hospital of Athens "Saint Savvas", Athens

- ★ General Oncology Hospital of Pireaus Metaxa, Pireaus

### Hungary

- ★ Országos Onkológiai Intézet, Budapest

- ★ National Korányi Institute for Pulmonology, Budapest

### Iceland

- ★ Landspítali, Reykjavik

### Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- ★ Beaumont RCSI Cancer Centre, Dublin
- ★ HSE West North West, University of Galway Cancer Centre, Galway

- ★ Cork University Hospital/University College Cork, Cork

- ★ Mater Private Network, Dublin

- ★ The Mater Misericordiae University Hospital, Dublin

- ★ St Vincent's UCD Cancer Centre, Dublin

### Italy

- ★ Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano

- ★ IRCCS Ospedale Policlinico San Martino, Genoa

- ★ Istituto Europeo di Oncologia, Milan

- ★ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan

- ★ Istituto Nazionale Tumori IRCCS

- ★ "Fondazione G.Pascale" (INT-Pascale), Naples

- ★ Istituto Nazionale Tumori Regina Elena, Rome

- ★ IRCCS Ospedale San Raffaele (OSR), Milan

- ★ Istituto Oncologico Veneto IRCCS-IOV, Padua

- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie

- ★ Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia

- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milan)

- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Turin)

- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari

- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)

- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)

- ★ Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)

- ★ ASST Spedali Civili di Brescia (SCH), Brescia

- ★ Fondazione IRCCS Policlinico San Matteo, Pavia

- ★ IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)

- ★ Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome

- ★ Istituto Dermatologico San Gallicano, Rome

### Jordan

- ★ King Hussein Cancer Center, Amman

### Latvia

- ★ Rīgas Austrumu klīniskā universitātes slimnīca, Riga

- ★ Paula Stradiņa Klīniskā universitātes slimnīca, Riga

### Lebanon

- ★ Naef K Basile Cancer Institute at the American University of Beirut Medical Center, Beirut

### Lithuania

- ★ National Cancer Institute, Vilnius

- ★ Vilnius University Hospital Santaros Klinikos, Vilnius

### Luxembourg

- ★ Institut National du Cancer (INC), Strassen

### Moldova

- ★ Public Health Institution Oncological Institute, Chisinau

### Norway

- ★ Oslo Universitetssykehus (OUS), Oslo

- ★ Helse Bergen HF (Haukeland University Hospital), Bergen

- ★ Akershus University Hospital Trust, Lørenskog

### Poland

- ★ Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw

- ★ Wielkopolskie Centrum Onkologii, Poznań

### Portugal

- ★ Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto), Porto

- ★ Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon

- ★ Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

### Romania

- ★ The "Prof. Dr. Ion Chiricuta" Institute of Oncology (IOC), Cluj-Napoca

- ★ Institutul Oncologic "Prof. Dr Alexandru Trestioreanu" Bucuresti, Bucharest

### Serbia

- ★ Oncology Institute of Vojvodina, Sremska Kamenica

### Slovakia

- ★ Biomedicinske centrum Slovenskej akadémie vied, Bratislava

### Slovenia

- ★ Onkološki Inštitut Ljubljana, Ljubljana

### Spain

- ★ Vall d'Hebron Barcelona Campus Hospitalari, Barcelona

- ★ Cancer Center Clínica Universidad de Navarra, Pamplona

- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia

- ★ Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)

- ★ Fundación Jiménez Díaz University Hospital, Madrid

- ★ Institut d'Oncologia de la Catalunya Sud Hospital Universitari Sant Joan de Reus, Reus

- ★ Hospital Universitario 12 de Octubre, Madrid

- ★ Clinic Barcelona Comprehensive Cancer Centre, Barcelona

- ★ Hospital Universitario Clínico San Carlos, Madrid

- ★ Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

- ★ Centro Integral Oncológico Clara Campal, Madrid

- ★ Hospital Universitario La Paz, Valencia

- ★ Hospital Universitario Ramon Y Cajal, Madrid

- ★ Hospital Clínico Universitario de Valencia (Departamento de Salud Clínico-Malvarrosa), Valencia

- ★ Hospital General Universitario Gregorio Marañón, Madrid

### Sweden

- ★ Karolinska Institute and University Hospital, Stockholm

- ★ Skånes Universitetssjukhus, Lund

- ★ Uppsala University Hospital, Uppsala

- ★ Sahlgrenska University Hospital, Göteborg

- ★ Linköping Comprehensive Cancer Center, Linköping

- ★ Norrlands Universitetssjukhus, Umeå

### Switzerland

- ★ Comprehensive Cancer Center Zürich (CCCZ), Zurich

### Tanzania

- ★ The Aga Khan Hospital, Dar es Salaam

### The Netherlands

- ★ OncoZON Cancer Network, Maastricht

- ★ Netherlands Cancer Institute, Amsterdam

- ★ Erasmus MC Cancer Institute, Rotterdam

- ★ Maastricht University Medical Centre+, Maastricht

- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen

- ★ Rijnstate, Arnhem

- ★ IKNL Integraal Kankercentrum Nederland, Utrecht

- ★ Radboudumc Centrum voor Oncologie, Nijmegen

### Turkey

- ★ Anadolu Sağlık Merkezi, Kocaeli

- ★ Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, Izmir

- ★ Türkiye Cancer Institute-TKE, Istanbul

### Ukraine

- ★ RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv

- ★ National Cancer Institute of Ukraine, Kyiv

### United Kingdom





- ★ The Christie NHS Foundation Trust, Manchester

- ★ Cancer Research UK Cambridge Centre, Cambridge


### Viet Nam

- ★ Bệnh viện K, Hanoi

## The OECI Board

	<b>President</b> Chairperson OECI EU Affairs Giovanni Apolone Italy		<b>Vice-President</b> Iwona Ługowska Poland		<b>Executive Secretary</b> Júlio Manuel Maia de Oliveira Portugal
	<b>Treasurer</b> Alfredo Budillon Italy		<b>Elected Member</b> ECO Representative Maja Čemažar Slovenia		<b>Elected Member</b> OECI Young Board Per Anders Sandström Sweden
	<b>Elected Member</b> Olga Balaoura Greece		<b>Elected Member</b> Chairperson Gender Equality Jacqueline M.L. Stouthard The Netherlands		<b>Elected Member</b> Christian Brands Germany
	<b>Elected Member</b> Steven le Gouill France		<b>Elected Member</b> Josep Tabernero Caturla Spain		





## Co-opted Members to the OECI Board

	<b>OECI General Manager</b> Claudio Lombardo Belgium - Italy		<b>OECIWORLD Chairperson</b> Thierry Philip Belgium - Italy
---	--	---	---

## Accreditation and Designation Programme

	<b>A&amp;D Board Chairperson</b> Jean-Benoît Burrión Belgium			<b>A&amp;D Quality Director</b> Simon Oberst Denmark
---	--	---	---	--

## Working Groups

	<b>Biobanks and Molecular Pathobiology WG Chairperson</b> Olli Carpén Finland		<b>Cancer Outcomes Research WG Chairperson</b> Cinzia Brunelli Italy
	<b>Cancer Economics WG Chairperson</b> Wim H. van Harten The Netherlands		<b>OECI for Patients</b> Delia Nicoară Romania

# OECI2025 ONCOLOGY DAYS

## General Oncology Hospital of Athens “Saint Savvas”

Γενικό Αντικαρκινικό Ογκολογικό  
Νοσοκομείο Αθηνών «Ο Άγιος Σάββας»  
<https://agsavvas-hosp.gr>



### Saint Savvas Oncology Hospital: A Pioneer in Cancer Therapy, Care and Research

Founded in 1935, Saint Savvas Oncology Hospital is the first Institution in Greece exclusively dedicated to cancer treatment and care. As a public entity since 1991, St Savas Hospital has become a cornerstone in the fight against cancer, providing comprehensive services in prevention, research, diagnosis and treatment.

### Commitment to Research Excellence

Saint Savvas Hospital participates in national and EU-funded research projects, involving translational, preclinical and clinical studies. The hospital has initiated phase I and II clinical trials for the active immunotherapy of patients with various types of cancer. Its Biobank, stores over 500 human biological specimens linked to detailed clinicopathological data.

### State-of-the-Art Core Facilities

The hospital houses advanced infrastructure including:

- **Cancer Genomics/Transcriptomics:** Genomics and transcriptomics platforms for novel biomarker and drug discovery.
- **Cell Imaging:** Advanced microscopic techniques and image analysis for cellular studies.
- **Flow Cytometry and cell-sorting:** for immune phenotyping and diagnostics.
- **Biostatistics:** Analysis of genomic/transcriptomic data using advanced software.
- **Cellular and Molecular Laboratory:** For the analyses of mechanistic pathways and signal transduction in the frame of translational research.

### Future commitments: Educational Contributions

Saint Savvas Hospital is committed to knowledge dissemination through its educational programs led by its scientific and administrative teams. These initiatives will focus on advanced biomedical and clinical research, health care quality, and public health policies.



Oncology Days Athens - Timetable

Oncology Days Athens - Timetable

	10 June 2025	11 June 2025
MORNING	<b>A&amp;D Board Meeting</b> 11.00 – 13.00  (Restricted to A&D Board Members)	<b>Accreditation &amp; Designation Session 1</b> 08.45 – 10.45
		Coffee Break 10.45 – 11.00
		<b>Accreditation &amp; Designation Session 2</b> 11.00 – 13.00
	Lunch	Lunch
AFTERNOON	<b>OECI Board &amp; Extended Board Meeting</b> 14.00 – 18.00  (Restricted to OECI Board and Extended Board Members)	<b>Scientific Conference Artificial Intelligence for Cancer Care</b> 14.00 – 16.00
		Coffee Break
		<b>OECI for Patients WG Session</b> Enhancing Patients Involvement in Cancer Care and Research 16.30 – 18.30
EVENING	Board Dinner	19.30 - Cocktail reception the roof garden of the Royal Olympic Hotel

	12 June 2025	13 June 2025
MORNING	<b>Quality of Life in Oncology</b>  <b>EUonQoL Session</b> 08.45 – 10.45	<b>Cancer Economics WG Session</b> 08.45 – 10.45
		<b>General Assembly Administrative Session &amp; Ceremony A&amp;D Certificates</b> 08.30 – 10.45 (Restricted to Delegates of OECI Members)
	Coffee Break 10.45 – 11.00	Coffee Break 10.45 – 11.00
	<b>Scientific Conference Oncology Care at Home</b> 11.00 – 13.00	<b>Open Discussion with Members &amp; close of the 2025 G.A.</b> 11.00 – 13.00 (Restricted to Delegates of OECI Members)
	Meeting of the OECI Young Board      Lunch      Cancer Economics WG Board Meeting	Lunch
AFTERNOON	<b>Comprehensive Cancer Infrastructures for the European Union</b>  <b>CCI4EU - CSA Session</b> 14.00 – 16.00	
	Coffee Break	
	<b>Accreditation &amp; Designation Auditors Session</b> 16.30 – 18.30	
EVENING	20.00 Gala Dinner The Zappeion Mansion (Peristilio Area)	

## Accreditation and Designation Session 1

This Session will update the audience on the latest developments in the A&D programme, and describe the main changes to the Standards and Manual following the 5-year revision. We will also focus on collaborations of cancer centres and OECI World.

**June 11<sup>th</sup>**

**08.45 - 10.45**

**Conference Room:  
Olympia**

08.45 **News and changes in A&D**

*Simon Oberst and Jean-Benoît Burrion*

09.00 **Standards Revision – what has changed?**

**New/revised Standards**

*Simon Oberst*

**Designation and research**

*Mef Nilbert*

**Network Standards**

*Simon Oberst*

**Q&A**

10.00 **Can twinning of Cancer Centres accelerate research?**

**Example of Budapest/Karolinska**

*Eva Jolly*

**Example of Curie/Curie**

*Iwona Ługowska*

10.30 **Presentation of OECI World plus South America network**

*Thierry Philip*

10.45 **Networking Coffee**

## Accreditation and Designation Session 2

This Session will focus on the quality tools we use to ensure quality of cancer care, such as patient pathways, multidisciplinary teams and metrics such as minimum surgical volumes. We will also hold another Directors' Forum as last year, to ask a panel of our Cancer Centre directors to discuss the main issues facing them today, and how OECI can help.

**June 11<sup>th</sup>**

**11.00 - 13.00**

**Conference Room:  
Olympia**

11.15 **Aspects of quality in the OECI network**

**Striving for research excellence**

*Johan van Lint*

**Formalising patient pathways in cancer**

*Peggy Richter*

**What do current studies/metrics indicate about volume/quality correlations?**

*Wim H. van Harten*

**Towards the agreement of minimum treatment volumes**

*Matthias Guckenberger*

12.15 **Directors' Panel:**

- What are the main issues facing Cancer Centres today, and how can OECI help?

- How can the A&D Programme add value to centres in re-accreditation?

*Chairpersons: Claire Noonan and Simon Oberst*

**Suggested directors:**

*Christian Brandts*

*Olga Balaoura*

*Maja Čemažar*

*Júlio Manuel Ramos Maia de Oliveira*

*Per Anders Sandström*

*Anna Sapino*

13.00 **Lunch**



### Harnessing Artificial Intelligence for Cancer Care

The integration of Artificial Intelligence (AI) in the healthcare sector promises better medicine. AI is used in medical diagnostics to analyse radiological images and identify pathologies with greater precision than traditional methods, improving in many cases the timeliness of diagnosis, the effectiveness of treatments, while improving recovery rates, fostering health innovation integration, and benefiting patients and society alike. In 2023 in Paris, we opened a dialogue on AI, and this Sessions aims to continue this conversation focusing on the use of AI to advance healthcare. By embracing AI, we aim not only to refine patient care but also improving operational efficiencies. Consistent with EU's vision for AI, we aspire to foster a multidisciplinary approach that integrates clinical and technological expertise, promotes preventive strategies, and raises health outcomes across Europe and beyond.

Chairpersons: *Iwona Ługowska* and *Georgios Koukourakis*

- 14.00 **How to translate AI in clinical cancer care**  
*Arsela Prelay*
- 14.20 **Artificial Intelligence as a Transformative Tool in Radiotherapy Planning: Enhancing Precision and Efficiency in Cancer Treatment**  
*Nikos Paragios and Maria-Angeliki Kalogeridi*
- 14.40 **AI applications in pathology**  
*Alexander Pearson*
- 15.00 **The Influence of Artificial Intelligence in Oncology Multidisciplinary Teams Decisions**  
*Leonor Cerdá Alberich*
- 15.20 **Artificial Intelligence privacy-enhanced techniques to mitigate privacy risks of patient's data**  
*Kyriakos Stefanides*
- 15.40 **Questions and answers**

June 11<sup>th</sup>

14.00 - 16.00

Conference Room:  
Olympia

### Enhancing Patients Involvement in Cancer Care and Research

This 2-hour session is designed to foster dialogue and collaboration among patient representatives, healthcare providers, researchers, hospital managers and policymakers to enhance patient involvement in cancer care and research. Organized in collaboration with OECI for Patients WG, the session will introduce and discuss their innovative Patient Involvement Model, which will provide a structured framework for integrating patient perspectives at every stage of cancer care and research. Through a combination of keynote presentations, panel discussions and interactive workshops, participants will explore real-world examples, challenges and strategies to effectively involve patients and NGOs in decision-making processes.

The session will highlight how the upcoming plan to adopt an OECI Patient Involvement Model in cancer care and research can empower patients, enhance care outcomes, and drive more impactful and inclusive research efforts. Attendees will leave with actionable insights and tools to implement patient-centric approaches in their respective organizations and practices, as well as a deeper understanding of the value of patient voices in shaping the future of cancer care and research.

### Proposed Agenda

Chairperson: *Delia Nicoară*

- 16.30 **Welcome & Opening Remarks**  
*Delia Nicoară and Claudio Lombardo*  
Overview of the session objectives & importance of patient involvement
- 16.40 **OECI4Patients WG: Key Updates & Plan of Action**  
*Delia Nicoară and Roxana Plesoianu*
- 16.50 **Keynote: Models of Patient Involvement in Cancer Care and Research**  
*Emmanuelle Hoche, Caitriona Higgins, Laura Del Campo*  
How patient perspectives are reshaping cancer care & research
- 17.20 **Panel Discussion: Best Practices in Patient Involvement**  
*Ivica Belina and Paulina Bravo*  
Exploring real-world case studies of patient involvement in decision-making and policy
- 17.50 **Interactive Session: Overcoming Barriers to Meaningful Engagement**  
*Iva Kirac*  
Group discussion on challenges and solutions for integrating patient voices
- 18.20 **Closing remarks and next steps**

June 11<sup>th</sup>

16.30 - 18.30

Conference Room:  
Olympia

## EUonQoL Session

### Results from the EUonQoL Pilot survey

Chairperson: **Cinzia Brunelli** and **Giovanni Apolone**

The session reports preliminary results of the EUonQoL validation pilot survey carried out in more than 40 cancer centres, mostly OECl affiliated, and addresses the project next steps in promoting the use of the EUonQoL-kit in the future.

### The EUonQoL-kit

**Cinzia Brunelli**

### The pilot survey

**Sara Iadecola**

### The EUonQoL-kit static version

**Montse Ferrer Forés**

### The EUonQoL-kit dynamic version

**Morten Aagaard Petersen**

### Patient involvement in the EUonQoL-Kit open-ended question analysis

**Nanne Bos**

### Guidelines for the implementation of EUonQoL kit

**Alen Brkic**



The improvement and preservation of quality of life (QoL) is one of the three pillars of the EC Mission on Cancer.

The project is aimed to contribute to the EU initiatives against Cancer, by developing the European Oncology Quality of Life Toolkit (EUonQoL-kit), a patient-centred unified tool for the assessment of quality of life among cancer patients and survivors.

The EUonQoL project is instrumental to the progress of the EU initiatives against cancer, with the specific aim of developing, piloting, validating, and exploiting the European Oncology Quality of Life toolkit (EUonQoL-Kit) among European cancer patients and survivors.

**June 12<sup>th</sup>**

**08.45 - 10.45**

**Conference Room:  
Olympia**

## Cancer Economics WG Session

### Treatments costs in cancer: bargaining, data and consequences

Chairperson: **Wim H. van Harten**

Treatment costs are increasing in cancer, caused by growing numbers of patients and especially costs of innovative medicines. In this session we will present data on actual costs and rebates of cancer drugs in EU countries, showing that this is an imperfect market in which transparency should be stimulated and bargaining positions of payers and providers should be improved. Use of real-world data and real world costs can assist providers in controlling their data position. The increased costs also add to the difficult position of cancer patients in facing socio-economic impact and we will discuss trends and policy proposals to improve identification of issues and guidance for patients.

### Attributes and costs of treatment in Hospital based Real World data

**Kevin Tittel**

### Bargaining and negotiation strategies on expensive drugs

**Joana Carvalho**

### Actual costs of cancer treatments

**Nora Franzen**

### Process mining on actual treatment patterns

**Lionel Perrier**

### Socio Economic Impact of Cancer: Status and Developments

**Michael Schlender**

### Questions/Discussion

The OECl Working Group on Cancer Economics focuses on a range of Health Economic and technology Assessment topics to stimulate promising innovations to timely reach the patient to combat inequalities in access and personal consequences of cancer related to Socio Economic factors. The WG objective is also to facilitate careful and explicit balancing of clinical benefits and financial impact of cancer treatments.

The WG pays also attention to those recent developments in health economics, such as value based pricing, budget impact expertise, which have the special interest of the OECl members and the whole cancer community.

**June 12<sup>th</sup>**

**08.45 - 10.45**

**Conference Room:  
Templar**

### Oncology Care at Home

Chairperson: **Michael Nikolaou** and **Mef Nilbert**

This session will serve as a platform to share insights, experiences, and solutions, contributing to a holistic understanding of the potential and challenges of oncology care at home. The transformative impact of telemedicine, digital health tools, and AI on enhancing accessibility, monitoring, and personalization in home oncology treatments.

1. **Bringing Care Home: Advancements in Home-Based Oncology Treatment Models: the case of Sweden**  
*Eva Jolly and Mef Nilbert*
2. **Can clinical research be done at home? The Oncopole experience in Toulouse-France**  
*Myriam Estrabaut*
3. **Navigating Challenges in Home-Based Cancer Care: Patient and Provider Perspectives**  
*Ivica Belina*
4. **Integrating Technology in Home Oncology Care: The Future is Now**  
*Kostas Athanasakis*
5. **From Hospital to Home, Ensuring Quality and Continuity in Oncology Care: Starting to think of hybrid service models**  
*Rutger Koornstra*

**June 12<sup>th</sup>**

**11.00 - 13.00**  
**Conference Room:**  
**Olympia**

**OECI**  
**for patients and**  
**with patients**

**Developing the future in**  
**Comprehensive Cancer Care**

## CCI4EU - CSA Session

The session will describe the achievements and the state of play of the action, which focuses on capacity building in research and innovation. The session will report on the 10 'Deep Dives' in developing Comprehensive Cancer Infrastructures, the Maturity Model, and the impact of regional conferences

- 14.00 **Introduction to CCI4EU**  
*Giovanni Apolone*
- 14.15 **Overview of achievements including Deep Dives**  
*Simon Oberst*
- 14.45 **Report on regional conferences and online courses**  
*Francesca Marangoni*
- 15.05 **Update on the Maturity Model**  
*Eva Jolly*
- 15.30 **Sustaining the solutions**  
*Carla Finocchiaro*
- 15.45 **Q&A and wrap up**  
*Chair: Simon Oberst*

## A&D Auditors Session

This session is for OECI auditors and also for centres interested in joining the A&D Programme. The session will focus in more detail on the agreed revised Standards and Processes for Manual 4.0 (for information, not for amendment).

- 16.30 **State of play of the A&D Programme**  
*Simon Oberst and Jean-Benoît Burrion*
- 17.00 **Revised Standards and Questionnaires - Highlights and Discussion**  
*Chair: Simon Oberst*
- 17.30 **Issues raised by audit chairs and auditors**  
*Chair: Claire Noonan*
- 18.00 **Future training opportunities**

**June 12<sup>th</sup>**

**14.00 - 16.00**  
**Conference Room:**  
**Olympia**

**June 12<sup>th</sup>**

**16.30 - 18.30**  
**Conference Room:**  
**Olympia**

### Draft Agenda

08.00 **Registration**

08.15 **Opening**

**General Assembly Constitution, welcome and approval of the Agenda**  
*Giovanni Apolone*

08.30 **Administrative Session**

*Chairperson: Giovanni Apolone*

**Point 1: Approval of the General Assembly Minutes of 14<sup>th</sup> June 2024**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Giovanni Apolone*

**Point 2: Approval of the Financial Statement 2024 and discharge to the Board**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Diego Pazienza*

**Point 3: OECI 2025 Provisional Budget**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Alfredo Budillon*

**Point 4: OECI Board composition for the coming years and renewal mandate for three Elected Members**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Giovanni Apolone*

**Point 5: New applications/resignation to the OECI membership, proposal of dismissals and requests of exemption from membership fee payment**

(vote requested: for full membership and fee exemption - decision to be taken by unanimity of the OECI Full Members present or represented; for associate membership (Type A-B-C) and dismissals – decision to be taken by simple majority of the OECI Full Members present or represented).

*Claudio Lombardo*

**Point 6: Proposals for the Oncology Days 2026 and the coming years**

*Giovanni Apolone and Iwona Ługowska*

10.45 Coffee Break

## CEREMONY FOR THE DELIVERY OF THE OECI A&D CERTIFICATES June 2024-June 2025

*Giovanni Apolone and Jean-Benoît Burrión*

Cancer Center Clínica Universidad de Navarra  
Cancer Institute AP-HP. Nord - Université Paris Cité  
Centre de lutte contre le cancer Eugène Marquis  
Cork University Hospital/University College Cork  
Erasmus MC Cancer Institute

Fundación Instituto Valenciano de Oncología  
General Oncology Hospital of Athens "Saint Savvas"  
Gustave Roussy

HSE West North West, University of Galway Cancer Centre  
Institut Paoli Calmettes

Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.

IRCCS Ospedale San Raffaele (OSR)

Karolinska Comprehensive Cancer Center

Leuven Kankerinstituut (LKI)

Linköping Comprehensive Cancer Center

TAYS Cancer Centre Tampere University Hospital

Trinity St. James's Cancer Institute

Uppsala University Hospital

## Open Discussion with Members & Close of the 2025

## General Assembly

11.00 **State of play of the OECI Presidential Strategy**

*Giovanni Apolone*

11.15 **Biobanks and Molecular Pathobiology WG**

*Olli Carpén*

11.30 **OECI Academy**

*Per Anders Sandström*

11.45 **OECI Young Board**

*Evy Lobbetael and Rebecca Amet*

12.00 **Open discussion with the Members**

*Chairpersons: Giovanni Apolone and Iwona Ługowska*

12.45 **Closure of the 2025 OECI General Assembly**

13.00 Lunch

## June 13<sup>th</sup>

## 11.00 - 13.00

*Conference Room:  
Olympia*



## Invited speakers

**Rebecca Amet**  
Dublin, Ireland

**Alfredo Budillon**  
Naples, Italy

**Montse Ferrer Forés**  
Barcelona, Spain

**Maria-Angeliki Kalogeridi**  
Athens, Greece

**Mef Nilbert**  
Lund, Sweden

**Thierry Philip**  
Lyon, France

**Giovanni Apolone**  
Milan, Italy

**Jean-Benoît Burrion**  
Brussels, Belgium

**Carla Finocchiaro**  
Milan, Italy

**Rutger Koornstra**  
Amsterdam, The Netherlands

**Claire Noonan**  
Dublin, Ireland

**Arsela Prelaj**  
Milan, Italy

**Kostas Athanasakis**  
Athens, Greece

**Olli Carpén**  
Helsinki, Finland

**Nora Franzen**  
Rotterdam, The Netherlands

**Georgios Koukourakis**  
Athens, Greece

**Simon Oberst**  
Bornholm, Denmark

**Peggy Richter**  
Dresden, Germany

**Olga Balaoura**  
Athens, Greece

**Joana Carvalho**  
Amsterdam, The Netherlands

**Matthias Guckenberger**  
Zurich, Switzerland

**Claudio Lombardo**  
Genoa, Italy

**Nikos Paragios**  
Athens, Greece

**Per Anders Sandström**  
Linköping, Sweden

**Ivica Belina**  
Zagreb, Croatia

**Maja Čemažar**  
Ljubljana, Slovenia

**Iva Kirac**  
Zagreb, Croatia

**Evy Lobbestael**  
Leuven, Belgium

**Diego Paziienza**  
Brussels, Belgium

**Anna Sapino**  
Turin, Italy

**Nanne Bos**  
Nivel, The Netherlands

**Leonor Cerdá Alberich**  
Valencia, Spain

**Sara Iadecola**  
Milan, Italy

**Iwona Ługowska**  
Warsaw, Poland

**Alexander Pearson**  
Chicago, US

**Michael Schlander**  
Heidelberg, Germany

**Christian Brandts**  
Frankfurt, Germany

**Júlio Manuel Ramos  
Maia de Oliveira**  
Porto, Portugal

**Eva Jolly**  
Stockholm, Sweden

**Francesca Marangoni**  
Milan, Italy

**Lionel Perrier**  
Lyon, France

**Kyriakos Stefanides**  
Athens, Greece

**Paulina Bravo**  
Santiago, Chile

**Laura Del Campo**  
Rome, Italy

**Caitriona Higgins**  
Dublin, Ireland

**Delia Nicoară**  
Cluj-Napoca, Romania

**Roxana Plesoianu**  
Brussels, Belgium

**Kevin Tittel**  
Amsterdam, The Netherlands

**Alen Brkic**  
Oslo, Norway

**Myriam Estrabaut**  
Toulouse, France

**Emmanuelle Hoche**  
Rouen, France

**Michael Nikolaou**  
Athens, Greece

**Morten Aagaard  
Petersen**  
Copenhagen, Denmark

**Wim H. van Harten**  
Amsterdam, The Netherlands

**Cinzia Brunelli**  
Milan, Italy

**Johan van Lint**  
Leuven, Belgium





# OECI2025 ONCOLOGY DAYS

## Cocktail reception

June 11<sup>th</sup> - 19.30 Hrs

*The Saint Savvas is honoured to welcome the OECI Delegates to the OECI Oncology Days 2025 on the Roof Garden of the Royal Olympic Hotel*



# OECI2025 ONCOLOGY DAYS

## OECI 2025 Gala Dinner

June 12<sup>th</sup> - 20.00 Hrs

It will take place at the Zappeion Megaron, part of the national heritage of Greek civilization, designed by T. Hansen (1874-1888). Evangelis Zappas, a Greek patriot and benefactor from North Epirus, envisaged the rebirth of the spirit of ancient Greece and devoted his life to the revival of the Olympic Games and the promotion of the Arts.

The Zappeion Megaron has been an active part of Greece's history and that of Hellenism, for the last 130 years. Cultural events of great importance take place within the precinct. Located in the center of Athens, the Zappeion Exhibition Hall is surrounded by some of the most important buildings in Athens, such as the Parliament building, the Tomb of the Unknown Soldier; the Maximou Palace, which is the official residence of the Prime Minister; the Foreign Ministry, and other public buildings. Nearby are the National Gardens and, opposite, on the side of the Ardittos Hill, the Panathinaic Stadium; Hadrian's Arch and the ancient Temple of the Olympian Zeus.





## **THE OEI 2025 INTERNATIONAL SCIENTIFIC COMMITTEE**

### **Presidents**

Giovanni Apolone and Olga Balaoura

### **Members**

Giovanni Apolone, Olga Balaoura, Christian Brandts, Jean-Benoît Burrión, Alfredo Budillon, Maja Čemažar, Cinzia Brunelli, Olli Carpén, Steven le Gouill, Claudio Lombardo, Iwona Ługowska, Delia Nicoară, Simon Oberst, Júlio Manuel Ramos Maiade Oliveira, Thierry Philip, Per Anders Sandström, Jacqueline M.L. Stouthard, Josep Tabernero Caturla, Wim H. van Harten

## **THE OEI 2025 ONCOLOGY DAYS SECRETARIATS**

GENOA: Daniela Garbarino, Diana Kochegarova, Alex White

BRUSSELS: Roxana Plesoianu

MILAN: Eleonora De Palo

ATHENS: Spiros Stavrianos, Vasiliki Gkioka

## **OEI 2025 ONCOLOGY DAYS COORDINATING OFFICE**

Claudio Lombardo

[oei@oei.eu](mailto:oei@oei.eu) - [www.oei.eu](http://www.oei.eu)

*In collaboration with:*

